

Hemerion Therapeutics successfully raises over €3.5 million: a new hope for the treatment of brain cancer

This new round of financing accelerates the implementation of international clinical trials aiming at validating Hemerion's solution against glioblastoma.

VILLENEUVE D'ASCQ, HAUTS-DE-FRANCE, FRANCE, April 14, 2022

/EINPresswire.com/ -- [Hemerion](#)

Therapeutics has successfully completed a €3.55 million seed round combining investment funds, business angels and a loan from Bpifrance. This new round of financing accelerates the implementation of international clinical trials aiming at validating Hemerion's therapeutic solution for the treatment of glioblastoma, the most aggressive brain cancer.



“

This is a real boost for the integration of our solution into the standard of care for glioblastoma, which affects nearly 30,000 new patients per year in Europe and the United States”

*Maximilien Vermandel,
founder of Hemerion
Therapeutics*

Hemerion's technology combines molecules and innovative laser treatment to selectively destroy cancer cells without damaging healthy tissue. The technology is based on a drug that selectively accumulates in cancer cells. When illuminated by a specific laser light, the drug causes tumor cells death through photochemical cytotoxic effect. Tumor cells are eliminated wherever the light penetrates.

Used as an add-on to surgery, before any adjuvant treatments, [Hemerion technology](#) eliminates cancer cells in places that are inaccessible to standard tumor resection. It holds particular promise for the treatment of glioblastoma, one of the most common and aggressive brain tumors. Hemerion Therapeutics has already initiated

its clinical program with a first conclusive clinical trial in patients harboring glioblastoma. Its

integration into the standard of care could significantly improve patient survival and quality of life.

A high level of seed funding that directly contributes to international [clinical development](#).

With a total amount of €3.55 million, this significant fundraising provides Hemerion's founders and their teams with excellent development prospects.

FIRA NORD EST 2 (Finovam gestion), CapTech Santé Nutrition and Nord France Amorçage funds and several business angels participated in this round with a total investment of €2.55 million. These equity operations are coupled with a €1 million seed loan from Bpifrance.

This new financing follows the first round achieved by Hemerion's founders, the University of Lille Foundation, Bpifrance and a French business angel entrepreneur. Hemerion had then raised a total of more than €1.7M in funding since the company's creation in September 2020.

This new round of funding will notably strengthen the company's regulatory, clinical and industrial resources and prepare for a Series A in 2023.

Accelerated clinical development , particularly in the U.S.

The company is already actively working with the Food and Drugs Administration (FDA) to obtain the Investigational New Drug (IND) label. This step precedes the implementation of a phase II clinical trial in the first half of 2023, in collaboration with Mount Sinai Hospital in New York.

The trial, involving 10 to 15 patients, will validate the safety of the new Heliance technology platform and foreshadow the clinical trial phase: a pivotal step in bringing Hemerion's solution for the treatment of glioblastoma to market.

Resources for new therapeutic applications in sight

This new funding also allows Hemerion to develop the portfolio of therapeutic applications for its technology. Several preclinical evaluations are already underway to validate the efficacy of the therapeutic solution in the treatment of other types of cancers.

About Hemerion Therapeutics

www.hemerion.com

About FINOVAM Gestion

www.finovamgestion.fr

About CAPTECH Santé Nutrition

www.finorpa.fr

About Nord France Amorçage
www.nord-france-amorcage.fr

Maximilien Vermandel
Hemerion Therapeutics
contact@hemerion.com

This press release can be viewed online at: <https://www.einpresswire.com/article/568419541>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.